School of Science, Yanshan University, Qinhuangdao, Hebei 066004, China.
School of Science, Yanshan University, Qinhuangdao, Hebei 066004, China; School of mathematics and statistics, Guangdong University of Technology, Guangzhou 510520, China.
Comput Biol Chem. 2024 Jun;110:108054. doi: 10.1016/j.compbiolchem.2024.108054. Epub 2024 Mar 19.
The computational method has been proven to be a promising means for pre-screening large-scale anticancer drug combinations to support precision oncology applications. Pioneering efforts have been made to develop machine learning technology for predicting drug synergy, but high computational cost for training models as well as great diversity and limited size in screening data escalate the difficulty of prediction. To address this challenge, we propose a simple machine learning framework, namely Similarity Network-based Synergy prediction (SNSynergy), for predicting synergistic effects towards new cell lines and new drug combinations by two locally weighted models CLSN and DCSN. This framework only requires a small amount of auxiliary data, like genomics information of cell lines and the molecular fingerprints or targets of drugs. Based on the assumption that similar cell lines and similar drug combinations have similar synergistic effects, CLSN and DCSN predict synergy scores through capturing individual synergy contributions of nearest cell line and drug combination neighbors, respectively. High correlations between predicted and measured synergy scores on two leading cancer cell line pharmacogenomic screening datasets (the O'Neil dataset and the NCI-ALMANAC dataset) demonstrate the effectiveness and robustness of SNSynergy. Many of the identified drug combinations are consistent with previous studies, or have been explored in clinical settings against the specific cancer type, showing that SNSynergy has the potential to supply cost-saving and effective high-throughput screening for prioritizing the most applicable cell lines and the most promising drug combinations.
该计算方法已被证明是一种有前途的方法,可用于预筛选大规模抗癌药物组合,以支持精准肿瘤学应用。已经做出了开创性的努力来开发用于预测药物协同作用的机器学习技术,但是训练模型的高计算成本以及筛选数据的多样性和有限性增加了预测的难度。为了解决这一挑战,我们提出了一种简单的机器学习框架,即基于相似网络的协同预测(SNSynergy),通过两个局部加权模型 CLSN 和 DCSN 对新细胞系和新药物组合的协同作用进行预测。该框架仅需要少量辅助数据,例如细胞系的基因组信息以及药物的分子指纹或靶标。基于相似细胞系和相似药物组合具有相似协同作用的假设,CLSN 和 DCSN 通过分别捕获最近的细胞系和药物组合邻居的个体协同作用贡献来预测协同作用得分。在两个领先的癌症细胞系药物基因组筛选数据集(O'Neil 数据集和 NCI-ALMANAC 数据集)上,预测协同作用得分与实测协同作用得分之间的高度相关性证明了 SNSynergy 的有效性和稳健性。许多鉴定的药物组合与先前的研究一致,或者已经在针对特定癌症类型的临床环境中进行了探索,表明 SNSynergy 有可能提供节省成本且有效的高通量筛选,以优先考虑最适用的细胞系和最有前途的药物组合。